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In this issue, Lo Iacono et al. present a retrospective study performed on 123 formalin-fixed, paraffin-embedded (FFPE) biopsies from 123 malignant mesothelioma (MM) 
patients, using next generation sequencing (NGS) with a commercially available library of 
genes that are frequently mutated in cancers. Biopsies were sequenced with the Ion Torrent 
platform, and positive results were validated by Sanger sequencing.1 Two limitations of 
this approach, acknowledged by the authors, are as follows: (1) as BAP1 and NF2 were not 
represented in the commercial library, their mutations status was analyzed using a differ-
ent custom-made library and (2) the particular targeted NGS methodology chosen in this 
article specifically detects small gene mutations, whereas this methodology cannot detect 
large genetic losses, gene amplifications and translocations, or epigenetic changes.
In a parallel study recently published in Cancer Research, Guo et al.2 performed 
whole exome sequencing on DNA and matched blood samples of 22 MM frozen biopsies 
from 22 patients collected in the operating room, integrated with the analysis of somatic 
copy number alterations. Exome capture libraries were sequenced on the Illumina HiSeq 
platform.2 In both studies, the biopsies were from patients previously treated with chemo-
therapy (100% of patients Lo Iacono et al. and 41% Guo et al.). Therefore, the well-docu-
mented mutagenic effects of chemotherapy on the cancer genome3 may have contributed to 
some of the mutations detected.
These studies1,2 present the first landscape view of the somatic genomic alterations 
in MM. Because the researchers1,2 used different experimental approaches, an exact com-
parison of the results is not possible. However, concordant data developed by independent 
research teams based in Europe and in the US, using different experimental strategies, 
provide reassurance on the reliability of these results. In fact, these two studies, which 
used robust statistical algorithms for the mutation analysis, show minor discrepancies and 
several corroborating findings.
In both studies, the number of nonsynonymous gene mutations was smaller than in 
other cancers. Lo Iacono et al. found that 20 of 52 “cancer” genes studied harbored varia-
tions in 25 of 123 (20%) of FFPE biopsies (including intronic, synonymous, nonsynony-
mous, and regulative mutations). These mutations were clustered in the two main “p53/
DNA repair” (TP53, SMACB1, and BAP1) and “PI3K-AKT” (PDGFRA, KIT, KDR, HRAS, 
PIK3CA, STK11, and NF2) pathways.
Guo et al. instead sequenced “only” the exome, but looked for all possible genes and 
found 490 mutated genes, of which 447 (97%) were mutated only in one biopsy, and found 
an average of 23 mutations per biopsy (range 2–51).
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Several factors may explain the different mutation fre-
quencies detected: the different sources of DNA (FFPE1 vs. 
frozen biopsies2), different platforms, study design and algo-
rithms used, and the fact that Lo Iacono et al.1 sequenced also 
the intronic regions (except for BAP1 and NF2). The genes 
most often mutated in both studies were BAP1, NF2, and 
CDKN2A.
Both studies detected frequent somatic nonsynonymous 
BAP1 mutations in 41%2 and 58%1 of MMs, respectively, con-
firming previous findings that detected somatic BAP1 muta-
tions in 22–61% of MMs.4–6 These mutations result in stop 
codons that produce truncated BAP1 proteins lacking the 
nuclear localization sequence or are mutations within the cata-
lytic subunit that impair BAP1 autodeubiquitination, which is 
required for nuclear localization.7 Therefore, these mutations 
are predicted to result in BAP1 proteins that cannot migrate 
to the nucleus and which may have aberrant deubiquitinase 
activity in the cytoplasm.8 Accordingly, Lo Iacono et al. found 
that 52% of 116 MM biopsies stained for nuclear BAP1—an 
indication of normal BAP1 activity—whereas 48% did not, 
an indication of mutated BAP1.1 Nuclear BAP1 staining cor-
related with presence/absence of DNA mutations (p = 0.001).
Both studies1,2 report frequent mutations of NF2, encod-
ing Merlin, a component of the Hippo signaling pathway,9 
with about 50% frequency, a value comparable with previ-
ous reports.10,11 Surprisingly, 92% of the specimens analyzed 
by Lo Iacono et al. showed NF2 expression by immunohis-
tochemistry.1 The authors propose that the genetic variations 
detected might deregulate NF2 without affecting protein 
expression and stability. Alternatively, the NF2 genetic muta-
tions detected are often of minor biological significance.
Lo Iacono et al. emphasize the possible role of muta-
tions found in the PIK3CA gene encoding the catalytic subunit 
of PI3K in favoring tumor progression. However, the authors 
acknowledge the need to study larger cohorts before conclu-
sions can be drawn.
Guo et al. performed an integrative pathway analysis 
of somatic mutations and focal somatic copy number altera-
tions: most recurrent alterations were in the MAPK and Wnt 
signaling pathways and in the cell cycle, with recurrent altera-
tions of CUL1, CDKN2A, and TP53, the last two matching the 
results obtained by Lo Iacono et al.
In summary, despite the different study designs and 
methodologies, these two NGS analyses of the MM genome 
reveal that inactivating mutations occur randomly and are 
rarely shared among MM biopsies, with the exception of 
BAP11,2 and to a lesser extent NF2, CDKN2A,1,2 and possibly 
CUL1.2
These results are in agreement with a large body of 
research that led to the conclusion that driver mutations (i.e., 
gene mutations present in all tumor cells in most cancers of 
the same type) are rare; a finding that significantly complicates 
the attempt to develop target therapies. In fact, the main goal 
of NGS tumor studies is to identify somatic driver mutations 
that would become potential therapeutic targets and/or clini-
cal biomarkers. Instead, the emerging picture indicates that 
each single tumor has its own specific sets of genetic altera-
tions. In addition to intertumor genetic heterogeneity, there is 
also significant intratumor genetic heterogeneity, as branched 
evolutionary growth generates genetic diversity in several 
tumor subclones. Thus, a single biopsy taken at a given time 
point is unlikely to be representative of the full spectrum of 
tumor genetic alterations. For example, over 60% of mutations 
detected by NGS in clear cell carcinomas of the kidney were 
not present in all tumor areas sampled.12 In the same study, 
mTOR mutations were found in seven of eight primary sites, 
but in none of three metastases.12 The studies of Lo Iacono et 
al. and of Guo et al. did not explore the issue of intratumor 
genetic heterogeneity. Based on studies in other tumor types,12 
and the recent findings that MMs are heterogeneous from start 
because they originate as polyclonal malignancies,13 it is easy 
to predict that MMs will also show marked intratumor hetero-
geneity, further complicating attempts to develop molecular 
therapies that may benefit a large number of patients.
However, and despite these considerations, the studies 
of Lo Iacono et al. and Guo et al. have succeeded in identifying 
recurrent genetic alterations in MMs that may be “actionable,” 
BAP1 being the most common. BAP1 is a nuclear ubiquitin 
carboxy-terminal hydrolase, associated with multiprotein 
complexes regulating key cellular pathways, including the 
cell cycle, cellular differentiation, cell death, gluconeogen-
esis, and DNA repair.8 When mutated in the germline, carri-
ers develop MMs, uveal and cutaneous melanomas, renal and 
cholangiocarcinomas, other malignancies, and often several 
cancers in combination.5,8 Moreover, several studies point at 
BAP1 as harboring the putative driver mutations for sporadic 
(nongenetically related) MMs. We5 and Bott et al.4 initially 
reported—in independent and parallel studies using Sanger 
sequencing from MM biopsies—that 22% and 23% of MM 
biopsies contained somatic BAP1 mutations. Yoshikawa et al.6 
reported that 61% of cell cultures derived from MM biopsies 
contained BAP1 mutations. Arzt et al.14 found that 60% of 
MM did not stain for nuclear BAP1, suggestive of inactivat-
ing mutations. To address the discrepancy in the frequency of 
BAP1 mutations detected in different studies, we used an inte-
grated genomic approach to study frozen MM biopsies, which 
included Sanger sequencing, Multiplex Ligation-Dependent 
Probe Amplification, cDNA sequencing, copy number analy-
ses, methylation studies of the BAP1 promoter, and immuno-
histochemistry. We found that 14 of 22 (63.6%) MM biopsies 
contained BAP1 mutations/inactivation. None of these meth-
odologies alone was able to capture all inactivating BAP1 
mutations. Thus, studies using methodology based exclusively 
on one type of molecular approach, such as Sanger sequenc-
ing4,5 or NGS,1,2 will underestimate the percent of MMs car-
rying BAP1 mutations. However, BAP1 nuclear staining was 
detected only in the eight specimens demonstrated to con-
tain wild-type BAP1 by the integrated genomic approach 
described above. Therefore, immunohistochemistry appeared 
to be capable of capturing the whole array of possible mecha-
nisms of BAP1 inactivation.15
Several findings underscore the apparent “driver” role 
of BAP1 in MMs and point at BAP1 as a potentially useful 
target: (1) multiple studies, including these two recent NGS1,2 
studies, found that BAP1 is frequently mutated in MM; (2) 
the persistence of BAP1 mutations in early lesions and in 
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MM biopsies established in cell culture, suggesting that BAP1 
mutations are an early event and that MM cells do not select 
against BAP1 mutations8; (3) the finding that, with rare excep-
tions, BAP1 nuclear staining is either detected in 100% of MM 
cells or it is not detected at all.15 Moreover, frequent somatic 
mutations in BAP1 are present in several malignancies,8 mak-
ing therapies to restore BAP1 activity in tumors relevant to 
many cancer patients.
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